Romain Remark | Clinical Program Manager
Innate Pharma

Romain Remark is a Program Manager at Innate Pharma, where he manages the development of IPH4502, a Nectin-4-targeted antibody-drug conjugate (ADC). He has over 10 years of experience in the biopharmaceutical industry, with expertise in oncology drug development, preclinical and translational research, and ADCs. Romain completed his PhD at the Cordeliers Research Center in Paris and his postdoctoral research at the Icahn School of Medicine at Mount Sinai in New York, before transitioning to industry.

Appearances:

Festival of Biologics Day 2 @ 15:30

Preclinical characterization of IPH4502, a differentiated Nectin-4-targeted exatecan ADC

IPH4502 is a differentiated Nectin-4 ADC with a high-affinity antibody with a non-overlapping epitope with enfortumab vedotin (EV), a potent exatecan payload to overcome key MMAE-related limitations and a proprietary stable linker slowing the release of free exatecan
In preclinical models, at same doses, IPH4502 shows superior efficacy to EV in bladder cancer models with low Nectin-4 expression, as well as in models of primary or induced resistance to EV
In preclinical models, IPH4502 shows efficacy in multiple non-urothelial cancer types (e.g., triple-negative breast, head and neck squamous cell, and esophageal cancers) and strong combination potential with PD-1 targeting agents

Romain Remark, Clinical Program Manager, Innate Pharma

last published: 21/Sep/26 11:05 GMT

back to speakers